2026-10-11T21:29:05Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34040702 2026-10-01T07:20:14Z category_37339 category_37357 category_37363 portal_1012 item_type_6 month_year_10_2026

Supplementary Figure S1 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT) Ferdinandos Skoulidis (16041866) Salma K. Jabbour (25153919) Edward B. Garon (15033509) Puneeth Iyengar (25153922) Giorgio Scagliotti (25153925) Loïc Ferrer (25153928) Guillaume Etchepare (25153931) Olivier Gallinato (25153934) Jérôme Faure (25153937) Paul Bernard (25153940) Thierry Colin (25153943) Philippe Menu (25153946) Yian Lin (25153949) Ling Cai (25153952) Ammar Ahmed Chaudhry (25153955) Amanda Remorino (25153958) Ross Stewart (14851015) Luisa Luciani-Silverman (25153961) Katy Miller (25153964) David Dellamonica (25153967) Jolyon Faria (25153970) Yiduo Zhang (25153973) Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers Imaging biomarkers Clinical Imaging Immunology Antibodies/immunoconjugates Immunotherapy Checkpoint blockade Lung Cancer <p>Supplementary Figure 1. Super T-learner architecture. The active arm refers to treatment with tremelimumab plus durvalumab and chemotherapy while the control arm refers to durvalumab plus chemotherapy</p> 2026-10-01T00:00:00Z Text Journal contribution 10.1158/1078-0432.34040702 https://figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_Utilizing_Machine_Learning_to_Identify_Multimodal_Signatures_for_Patients_Who_Would_Benefit_from_the_Addition_of_Tremelimumab_to_Durvalumab_and_Chemotherapy_TRIDENT_/34040702 CC BY